Portfolio
NeoGenomics expands its NGS portfolio with the launch of Neo Comprehensive(TM) – Solid Tumor CGP and Neo Comprehensive(TM) – Myeloid Disorders CGP
FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the expansion of its next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of several tests, including Neo Comprehensive – Solid Tumor, a comprehensive genomic profile (CGP) for solid Tumor Cancer Types and Neo Comprehensive – Myeloid Disorders, a CGP for Myeloid Neoplasms.
“We are committed to providing a broad spectrum of next-generation testing along with unparalleled service to improve patient care,” said Chris Smith, CEO of NeoGenomics. “With our new, easy-to-interpret reports, even faster turnaround times, and reduced sample requirements, these new tests provide clinicians with industry-leading testing options to help manage their cancer patients across different stages and types of disease.”
Neo Comprehensive – Solid Tumor is NeoGenomics’ largest pan-cancer solid tumor assay available to date. This CGP detects genomic changes most relevant to diagnosis, therapy selection, prognosis, and clinical trials. The panel includes 517 genes by both DNA and RNA NGS, microsatellite instability (MSI) and tumor mutation burden (TMB). This test is accompanied by an improved processing time and an optimized test report format.
Neo Comprehensive – Myeloid Disorders is available as an extension of NeoGenomics’ previous myeloid panel, making it the largest DNA and RNA NGS myeloid panel on the market with the most clinically actionable features, including single nucleotide variants (SNV), copy number variants (CNV) , insertions and deletions (InDel) and mergers.
Alongside the two product launches, NeoGenomics is also introducing two software resources to complement its testing menu: NeoAccess™, a test request tool that includes clinical decision support, pre-patient benefit testing and pre-approval support; and NeoSeek™, a platform that allows physicians to search their past test data to identify their patients who may be suitable biomarkers for a new therapy or clinical trial.
About Neo Comprehensive – Solid Tumor
Neo Comprehensive – Solid Tumor is a comprehensive solid tumor genomic profile (CGP) with a total of 517 genes covering: CNVs, SNVs, InDels, fusions, splice variants, TMB and MSI by DNA and RNA-NGS methods. In addition, this CGP offers an easy-to-interpret report format, improved test turnaround times, and reduced sample requirements.
About Neo Comprehensive – Myeloid Disorders
Neo Comprehensive – Myeloid Disorders is a comprehensive genome profile (CGP) analyzing 164 genes relevant to the assessment of myeloid neoplasms, detecting SNVs, InDels, CNVs and fusions using DNA and RNA-NGS methods. It is based on the latest guidelines and WHO 5th Edition classification covering a broad spectrum of myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), myeloproliferative neoplasms (MPN), myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement, mastocytosis, histiocytic neoplasms, and more.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, offering one of the most comprehensive oncology testing menus in the world to assist physicians in the diagnosis and treatment of cancer.
NeoGenomics is committed to connecting patients to life-changing therapies and studies. We believe that together with our partners we can help patients with cancer today and the next person diagnosed tomorrow. In fulfilling these commitments, NeoGenomics complies with all applicable state and federal privacy laws, provides patients with transparency and choice regarding how their data is handled and used through explicit permissions and our privacy practices notices, and has invested in leading technologies to ensure that the of data maintained by us is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, GA; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK, Rolle, Switzerland and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service networks and managed care organizations in the United States, and pharmaceutical companies in Europe and Asia.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are generally identified by the use of words such as “anticipate”, “expect”, “plan”, “could”, “would”, “may”, “will”, “believe”, “estimate”, “forecast”. ‘, ‘goal’, ‘project’, ‘guidance’, ‘plan’, ‘potential’ and other words of similar import, although not all forward-looking statements contain those words. These forward-looking statements relate to various topics, including statements about improving operational efficiencies, returning to profitable growth and the ongoing executive recruitment process. Any forward-looking statement contained in this press release is subject to a number of risks and uncertainties that may cause that actual results will differ materially from those expressed or implied. Applicable risks and uncertainties include, among other things, the Company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, identify and hire leadership candidates to continue acquiring B. new customers win, respond to the impact of the COVID-19 outbreak, offer new types of testing, integrate its acquisitions and otherwise implement its business plan, and the risks identified under Conv “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 23, 2023, and other information previously filed with the SEC.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless a different date is indicated), and we undertake no obligation to update or revise these statements. Our business is subject to significant risks and uncertainties, including those set forth above. Investors, prospective investors and others should carefully consider these risks and uncertainties.
For more information please contact:
NeoGenomics, Inc.
Vishal Sikri
President, Advanced Diagnostics
Vishal.Sikri@neogenomics.com
Telephone: +1-847-840-3702
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.Sweeney@neogenomics.com
T: +1-239-877-7474
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/743202/NeoGenomics-Expands-NGS-Portfolio-with-Launch-of-Neo-ComprehensiveTM–Solid-Tumor-CGP-and-Neo-ComprehensiveTM–Myeloid-Disorders-CGP
